CanadaBis CapitalTSXV:CANB Current Ratio is 1.33 as of Oct. 2025, which is 20% above its 10-year median of 1.11. The stock has 6 warning signs investors should review. Among 996 Drug Manufacturers companies, CanadaBis Capital ranks worse than 71.08% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. CanadaBis Capital's current ratio for the quarter that ended in Oct. 2025 was 1.33.
CanadaBis Capital has a current ratio of 1.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for CanadaBis Capital's Current Ratio or its related term are showing as below:
TSXV:CANB'
s Current Ratio Range Over the Past 10 Years
Min: 0.16 Med: 1.11 Max: 251.5
Current: 1.33
During the past 10 years, CanadaBis Capital's highest Current Ratio was 251.50. The lowest was 0.16. And the median was 1.11.
TSXV:CANB's Current Ratio is ranked worse than 71.08% of 996
companies
in the Drug Manufacturers industry
Industry Median: 2
vs TSXV:CANB: 1.33
CanadaBis Capital (TSXV:CANB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
CanadaBis Capital Current Ratio Related Terms
CanadaBis Capital Current Ratio Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs NPHC, BSPK, CPMD: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Current Ratio distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (TSXV:CANB) has a Current Ratio of 1.33 as of Oct. 2025. This is 20% above median its historical median of 1.11. Over the past decade, CanadaBis Capital's Current Ratio has ranged from 0.16 to 251.50. According to the industry distribution chart, CanadaBis Capital ranks #708 out of 996 companies in the Drug Manufacturers industry, placing it in the top 71.1%.
Is CanadaBis Capital's Current Ratio too high?
CanadaBis Capital's current Current Ratio of 1.33 is 20% above median its 10-year median of 1.11. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 251.50. The Drug Manufacturers industry median Current Ratio is 2.00. CanadaBis Capital's value of 1.33 is 33.5% below this industry median. Based on the distribution chart, CanadaBis Capital ranks #708 out of 996 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does CanadaBis Capital's Current Ratio compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #708 out of 996 companies for Current Ratio. This places CanadaBis Capital in the lower half of its industry. The industry median Current Ratio is 2.00. CanadaBis Capital's value of 1.33 is 33.5% below this benchmark. Historically, CanadaBis Capital's own Current Ratio has ranged from 0.16 to 251.50 over the past decade. While the company's 10-year median is 1.11 vs. the industry median of 2.00, CanadaBis Capital has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current Current Ratio of 1.33 is 33.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current Current Ratio is 1.33, which is 20% above median its own 10-year median of 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Current Ratio of 1.33. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Current Ratio is 1.33, which is 20% above median its 10-year median of 1.11 and 33.5% below the Drug Manufacturers industry median of 2.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Current Ratio is 1.33 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 